Unicycive Therapeutics Inc.

UNCY | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.77

-$0.03 (-0.63%)

At close: Sep 21, 2026, 4:00 PM ET

$4.77

$0 (0.00%)

Pre-market: Sep 22, 2026, 8:28 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.63%

(1D)

Rating

Updated: Aug 20, 2026

20.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $127.36M

1D Range

4.74 4.85

52W Range

3.71 8.74

Valuation (TTM)

PE -2.86

PB 2.39

EV/EBITDA -1.93

Valuation (NTM)

Forward PE 2.52

Forward PEG 0.01

Price Target $22

Cash Flow

FCF Yield -21.9%

SBC Adj. FCF Yield -25.3%

SBC Impact -15.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -50.0%

Dil EPS 3Y | 5Y 52.2% | 39.0%

FCF 3Y | 5Y -11.2% | -21.3%

Returns

ROA -48.9%

ROE -88.8%

ROIC -61.4%

Financial Health

Net Cash

$61.43M

Current Ratio 3.81

Interest Coverage -789.12

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyp...

Sector Healthcare

Industry Biotechnology

Employees 21

IPO Date Jul 11, 2021

Website www.unicycive.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$22

Upside

+361.22%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞